Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

roducts sold by the Company and its subsidiaries, including Makena™, and including competitive or responsive pricing changes;

(4) the possibility of not obtaining U.S. Food and Drug Administration ("FDA") approvals or delay in obtaining FDA approvals;

(5) new product development and launch, including the possibility that any product launch may be delayed or unsuccessful, including with respect to Makena™;

(6) acceptance of and demand for the Company's new pharmaceutical products, including Makena™, and for our current products upon their return to the marketplace, as well as the number of preterm births for which Makena™ may be prescribed and its safety profile and side effects profile and acceptance of the degree of patient access to, and pricing for, Makena™;

(7) the possibility that any period of exclusivity may not be realized, including with respect to Makena™, a designated Orphan Drug;

(8) the satisfaction or waiver of the terms and conditions for the continued ownership of the full U.S. and worldwide rights to Makena™ set forth in the previously disclosed Makena™ acquisition agreement, as amended;

(9) the consent decree between the Company and the FDA and the Company's suspension of the production and shipment of all of the products that it manufactures (other than the Potassium Chloride Extended Release Capsule products that are the subject of the FDA letter received September 8, 2010 allowing the return of those products to the marketplace) and the related nationwide recall affecting all of the other products that it manufactures, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item—1 "Business—(b)Significant Developments—Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decre
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered ... during 2008-2009, especially in North America and Europe. However, ... keeping to a growing trend. , The largest chunk ... the construction segment. In 2013, the key PVC application ... and rigid film. Moreover, the PVC was consumed in ...
(Date:10/30/2014)... On October 26th at the ... Chicago, leading applied stem cell research scientist Neil ... presented talks on New Techniques for Enhancing Stem ... Stem Cells. , Dr. Riordan focused on historical ... of AlphaGEMS that include: wound healing; inflammation and ...
(Date:10/30/2014)... Diego, CA (PRWEB) October 30, 2014 ... announced today that they have manually curated public data ... and non profit customers. the data is now ... manually curates and unifies public and internal data sources ... value and knowledge out of the data that becomes ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2
... London, July 20 There has been a recent upsurge ... space. While the economic downturn and related credit crunch has had ... which has including four mega M&As in the first half of ... ) , , "The real intention ...
... , ... has added to its portfolio of topical hormonal modulators with the acquisition of a ... systemic activity and will be developed for skin and hair disorders associated with increased ... ...
... , SAN FRANCISCO, July 17 VIA ... focused on the development of compounds for the treatment of ... Staff Determination letter, dated July 15, 2009, from the NASDAQ ... with the minimum $2,500,000 stockholders, equity requirement for continued listing, ...
Cached Biology Technology:Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4
(Date:10/30/2014)... is available in German . ... prompt our fellow humans to behave socially? This is ... in game theory. Previous studies assumed that it is ... scientists from the Max Planck Institute for Evolutionary Biology ... an influence on the cooperative behaviour of others. However, ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus Technologies, ... justice technology solutions for public safety, investigation, ... has deployed exciting enhancements to its THREADS™ ... to provide actionable intelligence and focused leads ... to drive technological innovation through identifying and ...
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... Capitol Hill, experts discussed how federally funded university research ... hearing, "Fueling Local Economies: Research, Innovation and Jobs," was ... by Rep. Carolyn Maloney (D-NY). Expert witnesses focused ... Samuel Stanley, president of Stony Brook University; Zachary Shulman, ...
... will present seven societal awards to distinguished ecologists at ... Pittsburgh. The meeting, which has the theme "Global Warming: ... future," draws a critical combination of more than 3,000 ... and consequences of global warming and to discuss the ...
... years as an herbal remedy to prevent or treat colds, ... medicines in North America. However, in spite of its popularity, ... immune system are conflicting. Now researchers from ... investigating the possibility that Echinacea has other potentially more important ...
Cached Biology News:NY state the focus of Congressional hearing on how research and innovation fuel local economies 2NY state the focus of Congressional hearing on how research and innovation fuel local economies 3Ecological Society of America announces 2010 award recipients 2Ecological Society of America announces 2010 award recipients 3Ecological Society of America announces 2010 award recipients 4
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Biology Products: